Login to Your Account

InterMune Prices Public Offering on Heels of Phase III IPF Data

By Trista Morrison

Tuesday, February 17, 2009
A week after Phase III pirfenidone data in idiopathic pulmonary fibrosis sent its stock up 36 percent, InterMune Inc. decided to sell 3.5 million shares in a public offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription